Topical Nitric Oxide Therapy to Treat Cervical Neoplasias and Prevent HPV-Associated Cancers
Abstract
The goal of this research is to develop a nitric oxide-releasing vaginal suppository that can be self-administered by female patients as a treatment for cervical neoplasias to eradicate latent HPV-18 infection and inhibit disease progression to cancer. The suppository will contain our proprietary NO-releasing drug, NVN1000, that has been shown to have antiviral efficacy against HPV-18. We have developed five prototype formulations using excipients determined to be compatible with NVN1000 and appropriate analytical methods for determining formulation stability. From the 12 week stability data, we selected a lead prototype candidate, although it appears refrigeration will be required to maintain stability. No further analysis of this formulation is planned. Through our collaborator at the University of Alabama Birmingham, we have also established a NVN1000 dose and application frequency that successfully inhibits HPV-18 replication in infected human raft cultures while minimizing cytotoxity and are in the process of evaluating the MOA of NO against E6 and E7 oncoprotiens.
Document Details
- Document Type
- Technical Report
- Publication Date
- Oct 01, 2022
- Accession Number
- AD1193022
Entities
People
- Carri Geer